You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
科倫藥業(002422.SZ):子公司向默沙東授權7個在研ADC項目收到1.75億美元首付款

格隆匯3月30日丨科倫藥業(002422.SZ)公吿稱,公司控股子公司四川科倫博泰生物醫藥股份有限公司(簡稱“科倫博泰”)於2022年12月22日與MERCK SHARP & DOHME LLC.(簡稱“默沙東”)簽署了《EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT》(《獨佔許可及合作協議》),科倫博泰將其管線中七種不同在研臨牀前ADC候選藥物項目以全球獨佔許可或獨佔許可選擇權形式授予默沙東在全球範圍內或在中國大陸、香港和澳門以外地區進行研究、開發、生產製造與商業化。科倫博泰保留部分授予獨佔許可的項目和有權保留授予獨佔許可選擇權的項目在中國大陸、香港和澳門研究、開發、生產製造和商業化的權利。

目前,雙方合作按既定計劃正常推進中,科倫博泰已於2023年3月30日收到默沙東支付的1.75億美元首付款(實際到賬金額須扣除按照相關法律計算的代扣代繳税金以及銀行手續費)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account